​

Funding Round

Series A - Affinia Therapeutics

Series A - Affinia Therapeutics

Investment Firm

Overview

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

Announced Date

Mar 31, 2020

Closed on Date

Mar 31, 2020

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

New Enterprise Associates

New Enterprise Associates

New Enterprise Associates is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

F-Prime Capital

F-Prime Capital

F-Prime Capital is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

6

Investor Name
Participant InvestorPartners Innovation Fund
Participant InvestorLonza
Participant InvestorF-Prime Capital
Participant InvestorAtlas Venture
Participant InvestorNew Enterprise Associates

Round Details and Background

Affinia Therapeutics raised $60000000 on 2020-03-31 in Series A

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 31, 2020
Series A - Affinia Therapeutics
6-60.0M
May 03, 2021
Series B - Affinia Therapeutics
15-110.0M

Recent Activity

There is no recent news or activity for this profile.